Benign Prostatic Hyperplasia (BPH) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034
Benign Prostatic Hyperplasia (BPH) Market Outlook
Thelansis’s “Benign Prostatic
Hyperplasia (BPH) Market Outlook, Epidemiology, Competitive Landscape, and
Market Forecast Report – 2024 To 2034" covers disease overview,
epidemiology, drug utilization, prescription share analysis, competitive
landscape, clinical practice, regulatory landscape, patient share, market
uptake, market forecast, and key market insights under the potential Benign
Prostatic Hyperplasia (BPH) treatment modalities options for eight major
markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
Benign Prostatic Hyperplasia (BPH)
Overview
Benign
prostatic hyperplasia (BPH), commonly known as an enlarged prostate, is a
non-cancerous condition prevalent in aging men, characterized by the excessive
growth of cells in the prostate gland. This enlargement often compresses the
urethra, which passes through the prostate, leading to a range of bothersome
lower urinary tract symptoms (LUTS) such as frequent or urgent urination,
nocturia (waking at night to urinate), difficulty initiating urination, a weak
or interrupted urine stream, and a sensation of incomplete bladder emptying.
While the exact cause is not fully understood, hormonal changes associated with
aging are believed to play a significant role. Although BPH is not cancerous
and does not increase the risk of prostate cancer, its symptoms can
significantly impact quality of life and, if left untreated, can lead to
complications such as urinary tract infections, bladder stones, bladder damage,
and, in severe cases, kidney damage.
Geography coverage:
G8 (United States, EU5 [France,
Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven by robust
research, including:
- In-depth interviews with leading KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR datasets
- Secondary research (e.g., peer-reviewed journal
articles, third-party research databases)
Deliverables format and
updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS Excel-based automated
dashboard)
- Epidemiology (MS Excel; interactive tool)
- Executive Insights (PowerPoint presentation)
- Others: regular updates, customizations, consultant
support
*As per Thelansis’s policy, we
ensure that we include all the recent updates before releasing the report
content and market model.
Salient features of Market
Forecast model:
- 10-year market forecast (2024–2034)
- Bottom-up patient-based market forecasts validated
through the top-down sales methodology
- Covers clinically and commercially-relevant patient
populations/ line of therapies
- Annualized drug-level sales and patient share
projections
- Utilizes our proprietary Epilansis and Analog tool
(e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources & assumptions
- Graphical and tabular outputs
- Users can customize the model based on requirements
Key business questions answered:
- How can drug development and lifecycle management
strategies be optimized across G8 markets (US, EU5, Japan, and China)?
- How large is the patient population in terms of
incidence, prevalence, segments, and those receiving drug treatments?
- What is the 10-year market outlook for sales and
patient share?
- Which events will have the greatest impact on the
market’s trajectory?
- What insights do interviewed experts provide on
current and emerging treatments?
- Which pipeline products show the most promise, and
what is their potential for launch and future positioning?
- What are the key unmet needs and KOL expectations for
target profiles?
- What key regulatory and payer requirements must be
met to secure drug approval and favorable market access?
- and more…
Comments
Post a Comment